In this research proposal, we aim to develop and optimise novel PROTACs targeting Aurora kinase A (AURKA) for potential therapeutic applications in cancer treatment. The project focuses on refining the structure of existing PROTACs, previously synthesised at the Laboratory of Medicinal Chemistry at UGent, and enhancing their efficacy, selectivity, and physicochemical properties. By systematically optimising the Cereblon ligand, linker, and AURKA binding moiety, we aim to create PROTACs with improved oral availability and therapeutic potential.